These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35531606)

  • 1. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
    Xia J; Li J; Tian L; Ren X; Liu C; Liang C
    J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
    Marsh S; Jimeno A
    Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
    Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
    Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.
    Huang R; Wu Y; Zou Z
    Epigenomics; 2022 Nov; 14(22):1449-1464. PubMed ID: 36601794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent inhibitors of EZH2: Design, synthesis and evaluation.
    Zhang Q; Chen X; Hu X; Duan X; Wan G; Li L; Feng Q; Zhang Y; Wang N; Yu L
    Biomed Pharmacother; 2022 Mar; 147():112617. PubMed ID: 34998031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
    Yang X; Xu L; Yang L
    Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
    Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
    Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
    Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
    J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of VHL-based EZH2 degraders for breast cancer.
    Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
    Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EZH2 as cancer therapy.
    Hanaki S; Shimada M
    J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancer of zeste homolog 2 (EZH2) inhibitors.
    Gulati N; Béguelin W; Giulino-Roth L
    Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EZH2 for cancer therapy: From current progress to novel strategies.
    Zeng J; Zhang J; Sun Y; Wang J; Ren C; Banerjee S; Ouyang L; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114419. PubMed ID: 35569264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugging histone methyltransferases in cancer.
    Richart L; Margueron R
    Curr Opin Chem Biol; 2020 Jun; 56():51-62. PubMed ID: 31981999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research Progress of Expression and Clinical Significant of EZH2 in Hematological Malignancies--Review].
    Hu JY; Ji YR; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):2097-2012. PubMed ID: 33283749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry.
    Wei L; Mei D; Hu S; Du S
    Future Med Chem; 2024 Aug; 16(15):1561-1582. PubMed ID: 39082677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
    Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
    Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
    Huang N; Liao P; Zuo Y; Zhang L; Jiang R
    J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
    Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
    Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
    Zhang T; Gong Y; Meng H; Li C; Xue L
    Clin Epigenetics; 2020 May; 12(1):72. PubMed ID: 32448308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.